The Radiologists’ Role in Diagnosing Lung Toxicity from Anti-Cancer Drugs
Join leading experts to sharpen your skills in diagnosing and treating lung toxicity from anti-cancer drugs during this free, one-hour webinar. This webinar is for health care professionals (HCPs) only and is sponsored by AstraZeneca and Daiichi Sankyo.
Webinar details
Date & time: Sept. 12, 2024; noon–1 p.m. CT
Price: Free
Enhance your understanding of interstitial lung disease (ILD)/pneumonitis related to anti-cancer drugs during this free, one-hour webinar (for HCPs only) sponsored by AstraZeneca and Daiichi Sankyo. Leading experts will share best practices and valuable insight related to ILD/pneumonitis risk factors, early diagnosis, the radiologist’s role within multi-disciplinary teams, and the monitoring and management of potential toxicity.
Learning objectives
- Enhance your understanding of interstitial lung disease (ILD)/pneumonitis related to anti-cancer drugs
- Discuss best practices related to ILD/pneumonitis risk factors, early diagnosis, the radiologist’s role within multi-disciplinary teams, and the monitoring and management of potential toxicity.
Speakers
Professor Julien Dinkel
Radiologist at Ludwig Maximilian University Hospital
Germany
Professor Nikolaus Kneidinger
Pulmonologist at LMU Klinikumder Universität München
Germany
This webinar is for HCPs only and is sponsored by AstraZeneca and Daiichi Sankyo.
DoP: August 2024 I JBN: Z4-67431